epidemiology and prevention of coronary artery disease martha gulati md, ms, facc, faha associate...
TRANSCRIPT
![Page 1: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/1.jpg)
Epidemiology and Prevention of Coronary Artery Disease
Martha Gulati MD, MS, FACC, FAHAAssociate Professor of Medicine and Clinical Public HealthSection Director of Women’s Cardiovascular Health and Preventive Cardiology Director, Cardiac Rehabilitation Ohio State University
![Page 2: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/2.jpg)
Learning Objectives
Describe primary and secondary prevention strategies to reduce cardiovascular disease risk
Describe non-modifiable and modifiable risk factors that impact the risk of cardiovascular disease (CVD)
Describe examples of currently accepted “best practice” guidelines for the treatment of cardiovascular disease
Identify behaviors that impact cardiovascular health
![Page 3: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/3.jpg)
Source: NCHS and NHLBI. A indicates CVD plus congenital CVD; B, cancer; C, accidents; D, CLRD; E, diabetes; and F, Alzheimer's disease.
Mozaffarian D et al. Circulation. 2015;131:e29-e322
CVD Compared with other Causes of Death for all males and females (United States: 2011)
![Page 4: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/4.jpg)
What is Prevention
Primordial prevention reduces the appearance of the mediating risk factors in the population, aiming to modify the conditions that generate and structure the unequal distribution of health-damaging exposures, susceptibilities among the population
Example: Ban on trans fats in NYC restaurants/ Smoking Bans in Bars
Primary prevention alters the levels of mediating risk factors after they appear in the population, focusing on individuals or groups of individuals and aiming to modify those factors that lead to an increased risk of CVD Intervening on a risk factor before the disease is clinically evident
Example: Treating hypertension or elevated LDL cholesterol in an asymptomatic individual with increased risk of future development of CAD
Secondary prevention alters risk factors related to disease after disease present Intervening on a risk factor or disease after the disease is clinically evident
Example: Use of statin therapy post MI
![Page 5: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/5.jpg)
Risk Factors for the Development of Coronary Artery Disease Non-modifiable
Age Race Family history/Genetics
1st degree male relative with heart disease <55 1st degree female relative with heart disease <65
![Page 6: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/6.jpg)
Risk Factors for the Development of Coronary Artery Disease Modifiable/preventable
Smoking Hypertension Hyperlipidemia Obesity Diabetes/Metabolic Syndrome Poor Fitness/Sedentary lifestyle Lack of Sleep
![Page 7: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/7.jpg)
Smoking causes more arterial damage in Women vs Men
Deaths due to smoking now equal to men (women smoke more & start younger)
“Social” smoking (1-4/day) kills
• 50% death
• 290% heart disease
• 500% lung cancer
Secondhand Smoking:
• Increases risk of CVD by 25-30%
Electronic Cigarettes
Thun MJ et al. NEJM 2013;368:351
vs never smokers
Tobacco and CVD
![Page 8: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/8.jpg)
Sleep and CVD
Sleeping <5 hours of sleep/night is associated with risk of CAD vs getting >5 hours of sleep
Each additional hour of sleep = lowering systolic blood pressure by ~17mm Hg
Study of ~10,000 adults, aged 32-49 years who sleep <7 hours/night are more likely to be obese
Insufficient sleep linked to increased risk for heart disease, colon cancer, breast cancer and diabetes
JAMA. 2008;300(24):2859-2866
![Page 9: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/9.jpg)
Prevalence of Hypertension* NHANES 2005-2008
20-34 35-44 45-54 55-64 64-74 75+0
10
20
30
40
50
60
70
80
90
100
11.1
25.1
37.1
54.0
64.0 66.7
6.8
19.0
36.2
53.3
69.3
78.5Men
Women
Age, years
Pe
rce
nt
of
Po
pu
lati
on
* Defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg, taking antihypertensive medication, or being told twice by a physician or other professional that one has hypertension.
Circulation. 2012;125::e12-e230 .
![Page 10: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/10.jpg)
NH White
Men
NH White
Wom
en
NH Bla
ck M
en
NH Bla
ck W
omen
Mex
ican
Am
eric
an M
en
Mex
ican
Am
eric
an W
omen
0
5
10
15
20
25
30
35
40
45
50
25.6
22.9
37.5 38.2
26.9
25.0
28.3 28.2
38.641.5
25.7 26.8
30.5
27.7
40.242.9
24.6 25.0
1988-1994 1999-2004 2005-2008
Per
cen
t o
f P
op
ula
tio
n
Source: NCHS and NHLBI. NH indicates non-Hispanic.
Roger VL et al. Published online in Circulation Dec. 15, 2010
Prevalence Trends for HTN in Adults by race ethnicitysex NHANES:1988-1994, 1999-2004, 2005-2008
![Page 11: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/11.jpg)
Blood Pressure
![Page 12: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/12.jpg)
DASH Diet: Dietary Approach to Stop Hypertension Fruits and Vegetables (9+) Whole grains Low-fat dairy (1) Low meat, fish, fowl (1) Low sat./total fat, cholesterol K+ and Ca++ rich Calorie neutral, 3 gm Na+
![Page 13: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/13.jpg)
DASH Study
48% women ( BP 133/85mmHg) 60% African Americans > 60% obese BP Results:
• ¯ 6.4/2.9 mmHg overall• Greater drop in African Americans and
higher baseline BP
Svetkey, Archives Int Med, 1999
![Page 14: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/14.jpg)
Modification Recommendation Avg SBP ReductionWeight Normal body wt 5-20 mm Hg/10 kgreduction (BMI 18-5-24.9 kg/m2)DASH eating fruits, vegetables, and 8-14 mm Hgplan low-fat diary
saturated and total fatDietary Na+ sodium intake to 2-8 mm Hgsodium 100 mmol per day reduction (2.4 g Na+ or 6 g NaCI)Aerobic Regular aerobic physical 4-9 mm Hgphysical activity (eg, brisk walking)activity at least 30 min/d, most
days of the weekModerate Men: Limit to 2 drinks/day 2-4 mm Hgalcohol Women and lighter weight consumption persons: Limit to 1 drink/day
21-55 mm HgJNC VII
Effects of Lifestyle on Blood Pressure
![Page 15: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/15.jpg)
Sex Differences in Aspirin for Primary CVD Prevention Meta-analysis; 6 RCT’s, n = 95,456, 51,342 women Total CVD risk reduction:
Men: ↓14%, (↓32% MI, ↔ stroke) Women: ↓12%, (↓17% stroke, ↔ MI)
No effect on CVD mortality Equal bleeding risk (↑~70%)
Berger et al, JAMA 295:306
![Page 16: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/16.jpg)
Physical Activity and Mortality: Harvard Alumni Study
Paffenbarger RS et al. NEJM 1986;314:605-13
![Page 17: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/17.jpg)
Men Women0
5
10
15
20
25
30
35
40
45
40.1
36.236.0
24.1
29.7
25.9
NH White NH Black Hispanic
Per
cen
t o
f P
op
ula
tio
n
Source: Pleis et al, 2010. NH indicates non-Hispanic. Percents are age-adjusted. Regular leisure-time physical activity is defined as 3 or more sessions per week of vigorous activity lasting at least 20 minutes or five or more sessions per week of light/moderate activity lasting at least 30 minutes.
©2010 American Heart Association, Inc. All rights reserved. Roger VL et al. Published online in Circulation Dec. 15, 2010
Prevalence of regular leisure-time physical activity among adults older than 18 years of age
by race ethnicity and sex (NHIS: 2009).
![Page 18: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/18.jpg)
Recommend Daily Moderate-Intense Activity for ~30 minutes
![Page 19: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/19.jpg)
Obesity (BMI ≥30 kg/m2)
Diabetes
1994
1994
2000
2000
No Data <14.0% 14.0-17.9% 18.0-21.9% 22.0-25.9% >26.0%
No Data <4.5% 4.5-5.9% 6.0-7.4% 7.5-8.9% >9.0%
CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at http://www.cdc.gov/diabetes/statistics
2010
2010
Age-Adjusted Prevalence of Obesity and Diagnosed Diabetes Among U.S. Adults Aged 18 Years or older
![Page 20: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/20.jpg)
NH White Males NH White Females
NH Black Males NH Black Females
Hispanic Males Hispanic Females
0
5
10
15
20
25
13.913.2
18.7
23.3
19.7 19.5
13.8
6.2
17.5
12.6
18.9
11.1
Overweight Obese
Per
cen
t o
f P
op
ula
tio
n
Source: Youth Risk Behavior Surveillance—United States, 2009. Table 90. NH indicates non-Hispanic.
©2010 American Heart Association, Inc. All rights reserved. Roger VL et al. Published online in Circulation Dec. 15, 2010
Prevalence of overweight and obesity among students in grades 9–12 by sex and race/ethnicity (YRBS: 2009).
![Page 21: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/21.jpg)
People Without Diabetes250.4 Million
Diabetes in the United States
• Incidence: 798,000 New cases per year• 90-95% of Diabetes is Type 2 Diabetes
![Page 22: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/22.jpg)
Metabolic Syndrome: Diagnostic Criteria
Abdominal obesity Waist circumference men > 40 in Waist circumference women > 35 in
Triglycerides > 150 mg/dL HDL
Men < 40 mg/dL
Women < 50 mg/dL BP > 130/85 Fasting glucose > 110 mg/dL
(Any 3 of 5 would meet diagnostic criteria)
![Page 23: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/23.jpg)
![Page 24: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/24.jpg)
Patients with Diabetes
![Page 25: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/25.jpg)
Risk of Cardiac Events in Patients With Diabetes
109
20
11
9 63819
3*
30
0
2
4
6
8
10
Age-adjusted annual rate/1,000
Men Women
Total CVD
CHD Cardiac failure
Intermittent claudication
Stroke
Riskratio
Risk to Women with Diabetes for all types of CVD Events (except stroke) is greater than MenP<0.001 for all values except *P<0.05.Wilson PWF, Kannel WB. In: Hyperglycemia, Diabetes and Vascular Disease. Ruderman N et al, eds. Oxford; 1992.
Age-adjusted Risk
Cardiovascular Event Men Women
Coronary Disease 1.52.2
Stroke 2.92.6
Peripheral Artery Disease 3.46.4
Cardiac Failure 4.4 7.8
All CVD Events 2.2 3.7
Women vs Men
![Page 26: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/26.jpg)
Sex Differences in Type I Diabetes and Risk of Death
26
26 studies: 214,114 individuals and 15,273 events
Women with Type 1 DM have ~40% greater excess risk of all-cause mortality, 2X excess risk of fatal and nonfatal vascular events compared with men with Type 1 DM
Mor
tality
Stroke
Renal
Diseas
e
Fatal
CVD
Incid
ent C
AD0
0.5
1
1.5
2
2.5
3
1.37 1.37 1.441.86
2.54
Risk Women:Men
Huxley RR et al. Lancet Diabetes Endocrinol. 2015;doi:10.1016/s2213-8587(14)70248-
![Page 27: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/27.jpg)
CHD Risk Increases as Plasma Cholesterol Increases
![Page 28: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/28.jpg)
NH White NH Black Mexican American180
185
190
195
200
205
210
206
204205
203
198
201
198
192
201
1988-94 1999-2004 2005-2008
Mea
n S
eru
m T
ota
l C
ho
lest
ero
l
Source: NCHS and NHLBI. NH indicates non-Hispanic.
©2010 American Heart Association, Inc. All rights reserved. Roger VL et al. Published online in Circulation Dec. 15, 2010
Trends in mean total serum cholesterol among adults ages equal or greater than 20 by race and survey year
(NHANES: 1988–1994, 1999–2004 and 2005–2008)
![Page 29: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/29.jpg)
ASCVD Risk Calculator (APP for that)
• For those 20-59 risk estimator provides lifetime risk estimate
• This is intended to drive discussions ofgreater adherence to heart-healthy lifestyle
• Part of risk discussion
![Page 30: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/30.jpg)
Statin Benefit Groups
Secondary Prevention LDL-C ≥ 190 mg/dL
Diabetes – 40 to 75 yrsLDL-C 70-189 mg/dl
Primary Prevention – 40 to 75 yrs
LDL-C 70-189 mg/dlASCVD Risk ≥ 7.5 %
Rx: Moderate intensity or high intensity statin
Statin Rx not automatic,requires clinician-patient discussion
Rx: Optimal benefit with high intensity statins lower LDL-C ≥ 50%Use moderate intensity if age >75 or can’t tolerate high intensity
![Page 31: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/31.jpg)
Statin Effects on Major Vascular Events
CTT. Lancet 2008 371: 117-125
EndpointEvents (%)
Treatment Control Rate Ratio (CI)
Non-fatal MI 2001 (4·4) 2769 (6·2) 0·74 (0·70 – 0·79)CHD death 1548 (3·4) 1960 (4·4) 0·81 (0·75 – 0·87)
Any major coronary event 3337 (7·4) 4420 (9·8) 0·77 (0·74 – 0·80)
CABG 713 (3·3) 1006 (4·7) 0·75 (0·69 – 0·82)PTCA 510 (2·4) 658 (3·1) 0·79 (0·69 – 0·90)Unspecified 1397 (3·1) 1770 (3·9) 0·76 (0·69 – 0·84)
Any coronary revascularisation 2620 (5·8) 3434 (7·6) 0·76 (0·73 – 0·80)
Haemorrhagic stroke 105 (0·2) 99 (0·2) 1·05 (0·78 – 1·41)Presumed ischaemic stroke 1235 (2·8) 1518 (3·4) 0·81 (0·74 – 0·89)
Any stroke 1340 (3·0) 1617 (3·7) 0·83 (0·78 – 0·88)
Any major vascular event 6354 (14·1) 7994 (17·8) 0·79 (0·77 – 0·81)
0·5 1·0 1·5
Favors statin
![Page 32: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/32.jpg)
24.533.8 31.7
76.8
15.0 17.18.2
3.2
32.9
23.2
22.9
38.441.2
30.4
72.2
33.2
45.2 46.641.7
61.4
0.0
20.0
40.0
60.0
80.0
100.0
CurrentSmoking
Body MassIndex
PhysicalActivity
Healthy DietScore
TotalCholesterol
BloodPressure
FastingPlasmaGlucose
Pe
rce
nta
ge
Poor Intermediate Ideal
©2010 American Heart Association, Inc. All rights reserved. Roger VL et al. Published online in Circulation Dec. 15, 2010
Prevalence Estimates for poor, intermediate and ideal CV Health for Metrics of CVD Health based on AHA 2020 goalsUS adults >20 years of age, NHANES 2005-2006 (data as of 1/1/2010
![Page 33: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/33.jpg)
AHA/ACC Secondary Prevention Guidelines:
33
All Patients Should Receive Therapy:• Smoking cessation• Anti-platelet therapy• Beta blocker post-MI or with LV dysfunction• ACE-inhibitor (or ARB) if post-MI or LVEF 40%
• Add aldosterone blockade if CHF• Statin • Weight loss of 5-10% if BMI ≥ 30 kgm2
• Physical activity at least 30 minutes per day• Cardiac Rehabilitation- Angina/Post MI/ Post-stent/ Post valve
surgery/Heart Failure• Influenza vaccine
![Page 34: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/34.jpg)
Aspirin
![Page 35: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/35.jpg)
Clopidogrel
![Page 36: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/36.jpg)
Beta-Blocker
![Page 37: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/37.jpg)
Ace Inhibitor
![Page 38: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/38.jpg)
HMG-CoA Reductase Inhibitor: Secondary Prevention
![Page 39: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/39.jpg)
Effects of Cardiac Rehabilitation
Outcome Mean 95% conf. intervals p-value
Total Mortality* -20% (-7 to -32%) p=.005 Cardiac Mortality* -26% (-10 to -29%) p=.002 Nonfatal MI -21% (-43 to 9%) p=.15 CABG -13% (-35 to 16%) p=.4 PCI -19% (-51 to 34%) p=.4
Taylor, et al Am J of Medicine 2004; 116:682-97
![Page 40: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/40.jpg)
Exercise for 2° CHD Prevention: Why?
Improved functional capacity Improved CAD risk factor control Reduced depression Improved survival
Though originally designed for coronary artery disease patients, there is accumulating evidence that patients with other cardiac diseases will also benefit from cardiac rehabilitation
![Page 41: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/41.jpg)
Medication Adherence after MI
Statins: 75% at discharge, 44% 3 years BB: 84% at discharge, 48% at 3 years ACEI: 62% at discharge, 43% at 3 years
Am J Med. 2009 Oct;122(10):961.e7-13.
![Page 42: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/42.jpg)
Medication Adherence with Cardiac Rehabilitation All patients, not just post-MI
Squires et al, JCRP 2008;28:180-186
![Page 43: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/43.jpg)
Cardiovascular Prevention
Broad implementation of preventive recommendations can reduce the epidemic of cardiovascular disease
Patient and community education, screening of cardiovascular risk factors with implementation of appropriate interventions, in addition to further research to improve our understanding of the atherosclerotic process will be necessary to make significant impact
Risk assessment tools are available to identify individuals who may benefit from more aggressive approaches, including both therapeutic lifestyle changes and pharmacologic agents
It will require the coordinated efforts of public health experts, primary care physicians and cardiovascular specialists to further impact the incidence of cardiovascular diseases and its associated morbidity and mortality
![Page 44: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/44.jpg)
Prevention of Heart Disease Quiz
![Page 45: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/45.jpg)
Thank you for completing this module
If you have any questions or would like to offer me some feedback, please contact me:
![Page 46: Epidemiology and Prevention of Coronary Artery Disease Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine and Clinical Public Health Section](https://reader038.vdocuments.us/reader038/viewer/2022103005/56649e0d5503460f94af6e90/html5/thumbnails/46.jpg)
Survey
We would appreciate your feedback on this module. Click on the button below to complete a brief survey. Your responses and comments will be shared with the module’s author, the LSI EdTech team, and LSI curriculum leaders. We will use your feedback to improve future versions of the module.
The survey is both optional and anonymous and should take less than 5 minutes to complete.
Survey